{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:52:40Z","timestamp":1787237560668,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95\u20131.24;\n                      <jats:italic>p<\/jats:italic>\n                      : 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55\u201325.81;\n                      <jats:italic>p<\/jats:italic>\n                      : 0.22).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>identifier PROSPERO (CRD42022324150).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2023.1202927","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T07:56:51Z","timestamp":1691135811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Niza","family":"Alva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brando","family":"Ortiz-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizbet S.","family":"Montes-Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Cotrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Caballero-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshuan J.","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.25122\/jml-2022-0060","article-title":"Retinopathy of prematurity, a two-year experience at the ROP screening unit from AL-Zahraa teaching hospital, AL-Najaf, Iraq","volume":"15","author":"Neamah","year":"2022","journal-title":"J Med Life"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14.e1","DOI":"10.1016\/j.jaapos.2022.10.007","article-title":"Quantitative analysis of tear angiogenic factors in retinopathy of prematurity: a pilot biomarker study","volume":"27","author":"Magnani","year":"2023","journal-title":"J AAPOS"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21977","DOI":"10.1038\/s41598-022-26229-4","article-title":"Risk factors associated with retinopathy of prematurity development and progression","volume":"12","author":"De Las Rivas Ram\u00edrez","year":"2022","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/08820538.2022.2152706","article-title":"Molecular mediators and regulators of retinal angiogenesis","volume":"38","author":"Vishwakarma","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s10792-022-02576-z","article-title":"Systemic biomarkers of retinopathy of prematurity in preterm babies","volume":"43","author":"Sehgal","year":"2022","journal-title":"Int Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1007\/s00417-022-05628-3","article-title":"Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis","volume":"260","author":"Xia","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B8","article-title":"Fighting ROP with anti-VEGF therapy","author":"Roach","year":"2019","journal-title":"EyeNet Magazine (Am Acad Ophthalmol)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.ophtha.2018.04.018","article-title":"How does the standard of care evolve? Anti\u2013vascular endothelial growth factor agents in retinopathy of prematurity treatment as an example","volume":"125","author":"Chiang","year":"2018","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Syn Meth"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/jcm11092615","article-title":"Efficacy of colchicine in the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"11","author":"Toro-Huamanchumo","year":"2022","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/sim.7665","article-title":"Multistep estimators of the between-study variance: the relationship with the paule-mandel estimator: multi-step estimators of the between-study variance","volume":"37","author":"Van Aert","year":"2018","journal-title":"Stat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/children9050589","article-title":"The efficacy of CPAP in neonates with meconium aspiration syndrome: a systematic review and meta-analysis","volume":"9","author":"Toro-Huamanchumo","year":"2022","journal-title":"Children"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41390-020-0902-x","article-title":"Short-term efficacy of umbilical cord milking in preterm infants: systematic review and meta-analysis","volume":"89","author":"Barboza","year":"2021","journal-title":"Pediatr Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/jcm11112998","article-title":"Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Barboza","year":"2022","journal-title":"JClin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jrsm.1517","article-title":"On ratio measures of heterogeneity for meta-analyses","volume":"13","author":"Cairns","year":"2022","journal-title":"Res Synth Methods"},{"key":"B18","author":"Akl","year":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or Laser in the RAINBOW trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"B24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year Outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Trans Vis Sci Tech"},{"key":"B26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13224-022-01660-9","article-title":"Comparison of retinopathy of prematurity incidence in preterm infants of mothers with preeclampsia and infants of healthy mothers","volume":"72","author":"Boskabadi","year":"2022","journal-title":"J Obstet Gynecol India"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108507","DOI":"10.1016\/j.exer.2021.108507","article-title":"Prostaglandin E2 promotes pathological retinal neovascularisation via EP4R-EGFR-Gab1-AKT signaling pathway","volume":"205","author":"Xie","year":"2021","journal-title":"Exp Eye Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional Laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-620X.142592","article-title":"Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity","volume":"7","author":"Bachu","year":"2014","journal-title":"Oman J Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2721578","article-title":"Speed of retinal vascularization in retinopathy of prematurity: risk and protective factors","volume":"2019","author":"Solans P\u00e9rez De Larraya","year":"2019","journal-title":"Biomed Res Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/IAE.0000000000002837","article-title":"Anatomical and visual outcomes in stage 5 retinopathy of prematurity with microincision vitrectomy surgery","volume":"41","author":"Sen","year":"2021","journal-title":"Retina"},{"key":"B34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"B35","doi-asserted-by":"publisher","first-page":"145695","DOI":"10.1016\/j.gene.2021.145695","article-title":"Hypoxia-induced retinal pigment epithelium cell-derived bFGF promotes the migration and angiogenesis of HUVECs through regulating TGF-\u03b21\/smad2\/3 pathway","volume":"790","author":"Chen","year":"2021","journal-title":"Gene"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.61.2.3","article-title":"Epithelial membrane protein 2 (EMP2) promotes VEGF-induced pathological neovascularization in murine oxygen-induced retinopathy","volume":"61","author":"Sun","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02713683.2019.1681004","article-title":"Vascular regeneration for ischemic retinopathies: hope from cell therapies","volume":"45","author":"Bertelli","year":"2020","journal-title":"Curr Eye Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.semperi.2015.12.006","article-title":"Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity","volume":"40","author":"Beharry","year":"2016","journal-title":"Semin Perinatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.18240\/ijo.2022.05.10","article-title":"Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity","volume":"15","author":"Zou","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on Serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1202927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T07:56:54Z","timestamp":1691135814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1202927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":40,"alternative-id":["10.3389\/fped.2023.1202927"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1202927","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"article-number":"1202927"}}